233 related articles for article (PubMed ID: 22015290)
1. Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin.
Goodwin PJ; Stambolic V
Breast; 2011 Oct; 20 Suppl 3():S31-5. PubMed ID: 22015290
[TBL] [Abstract][Full Text] [Related]
2. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin.
Wysocki PJ; Wierusz-Wysocka B
Expert Rev Mol Diagn; 2010 May; 10(4):509-19. PubMed ID: 20465505
[TBL] [Abstract][Full Text] [Related]
3. Metformin: taking away the candy for cancer?
Jalving M; Gietema JA; Lefrandt JD; de Jong S; Reyners AK; Gans RO; de Vries EG
Eur J Cancer; 2010 Sep; 46(13):2369-80. PubMed ID: 20656475
[TBL] [Abstract][Full Text] [Related]
4. New perspective for an old antidiabetic drug: metformin as anticancer agent.
Leone A; Di Gennaro E; Bruzzese F; Avallone A; Budillon A
Cancer Treat Res; 2014; 159():355-76. PubMed ID: 24114491
[TBL] [Abstract][Full Text] [Related]
5. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer.
Guppy A; Jamal-Hanjani M; Pickering L
Future Oncol; 2011 Jun; 7(6):727-36. PubMed ID: 21675836
[TBL] [Abstract][Full Text] [Related]
6. Is it time to test metformin in breast cancer clinical trials?
Cazzaniga M; Bonanni B; Guerrieri-Gonzaga A; Decensi A
Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):701-5. PubMed ID: 19240238
[TBL] [Abstract][Full Text] [Related]
7. Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark.
Bosco JL; Antonsen S; Sørensen HT; Pedersen L; Lash TL
Cancer Epidemiol Biomarkers Prev; 2011 Jan; 20(1):101-11. PubMed ID: 21119073
[TBL] [Abstract][Full Text] [Related]
8. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.
Zakikhani M; Dowling R; Fantus IG; Sonenberg N; Pollak M
Cancer Res; 2006 Nov; 66(21):10269-73. PubMed ID: 17062558
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents.
Goodwin PJ; Stambolic V; Lemieux J; Chen BE; Parulekar WR; Gelmon KA; Hershman DL; Hobday TJ; Ligibel JA; Mayer IA; Pritchard KI; Whelan TJ; Rastogi P; Shepherd LE
Breast Cancer Res Treat; 2011 Feb; 126(1):215-20. PubMed ID: 20976543
[TBL] [Abstract][Full Text] [Related]
10. IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer.
Dool CJ; Mashhedi H; Zakikhani M; David S; Zhao Y; Birman E; Carboni JM; Gottardis M; Blouin MJ; Pollak M
Endocr Relat Cancer; 2011 Dec; 18(6):699-709. PubMed ID: 21946410
[TBL] [Abstract][Full Text] [Related]
11. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
[TBL] [Abstract][Full Text] [Related]
12. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.
Hadad S; Iwamoto T; Jordan L; Purdie C; Bray S; Baker L; Jellema G; Deharo S; Hardie DG; Pusztai L; Moulder-Thompson S; Dewar JA; Thompson AM
Breast Cancer Res Treat; 2011 Aug; 128(3):783-94. PubMed ID: 21655990
[TBL] [Abstract][Full Text] [Related]
13. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study.
Niraula S; Dowling RJ; Ennis M; Chang MC; Done SJ; Hood N; Escallon J; Leong WL; McCready DR; Reedijk M; Stambolic V; Goodwin PJ
Breast Cancer Res Treat; 2012 Oct; 135(3):821-30. PubMed ID: 22933030
[TBL] [Abstract][Full Text] [Related]
14. Is it the time for metformin to take place in adjuvant treatment of Her-2 positive breast cancer? Teaching new tricks to old dogs.
Yurekli BS; Karaca B; Cetinkalp S; Uslu R
Med Hypotheses; 2009 Oct; 73(4):606-7. PubMed ID: 19560877
[TBL] [Abstract][Full Text] [Related]
15. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation.
Gallagher EJ; LeRoith D
Ann N Y Acad Sci; 2011 Dec; 1243():54-68. PubMed ID: 22211893
[TBL] [Abstract][Full Text] [Related]
16. Metformin and gynecologic cancers.
Stine JE; Bae-Jump V
Obstet Gynecol Surv; 2014 Aug; 69(8):477-89. PubMed ID: 25144611
[TBL] [Abstract][Full Text] [Related]
17. Metformin in cancer: translational challenges.
Dowling RJ; Niraula S; Stambolic V; Goodwin PJ
J Mol Endocrinol; 2012 Jun; 48(3):R31-43. PubMed ID: 22355097
[TBL] [Abstract][Full Text] [Related]
18. Current indications for metformin therapy.
Tankova T
Rom J Intern Med; 2003; 41(3):215-25. PubMed ID: 15526505
[TBL] [Abstract][Full Text] [Related]
19. [Anti-cancer activity of metformin: new perspectives for an old drug].
Beck E; Scheen AJ
Rev Med Suisse; 2010 Sep; 6(260):1601-7. PubMed ID: 20853715
[TBL] [Abstract][Full Text] [Related]
20. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase.
Algire C; Amrein L; Zakikhani M; Panasci L; Pollak M
Endocr Relat Cancer; 2010 Jun; 17(2):351-60. PubMed ID: 20228137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
